Literature DB >> 25850945

Mitochondrial DNA Polymerase γ Mutations and Their Implications in mtDNA Alterations in Colorectal Cancer.

Katarzyna Linkowska1, Arkadiusz Jawień2, Andrzej Marszałek3, Boris A Malyarchuk4, Katarzyna Tońska5, Ewa Bartnik5,6, Katarzyna Skonieczna1, Tomasz Grzybowski1.   

Abstract

Mitochondrial DNA was found to be highly mutated in colorectal cancer cells. One of the key molecules involved in the maintenance of the mitochondrial genome is the nuclear-encoded polymerase gamma. The aim of our study was to determine if there is a link between polymorphisms within the polymerase gamma gene (POLG) and somatic mutations within the mitochondrial genome in cancer cells. We investigated POLG sequence variability in 50 colorectal cancer patients whose complete mitochondrial genome sequences were determined. Relative mtDNA copy number was also determined. We identified 251 sequence variants in the POLG gene. Most of them were germline-specific (∼92%). Twenty-one somatic changes in POLG were found in 10 colorectal cancer patients. We have found no association between the occurrence of mtDNA somatic mutations and the somatically occurring variants in POLG. MtDNA content was reduced in patients carrying somatic variants in POLG or germline nucleotide variants located in the region encoding the POLG polymerase domain, but the difference did not reach statistical significance. Our findings suggest that somatic mtDNA mutations occurring in colorectal cancer are not a consequence of somatic mutations in POLG. Nevertheless, POLG nucleotide variants may lead to a decrease in mtDNA content, and consequently result in mitochondrial dysfunction.
© 2015 John Wiley & Sons Ltd/University College London.

Entities:  

Keywords:  POLG; colorectal cancer; mtDNA; somatic mutations

Year:  2015        PMID: 25850945     DOI: 10.1111/ahg.12111

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  8 in total

Review 1.  Mitochondrial DNA variants in colorectal carcinogenesis: Drivers or passengers?

Authors:  Edoardo Errichiello; Tiziana Venesio
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-09       Impact factor: 4.553

2.  POLG Gene Variants in Cervical Cancer Patients and Their Associations with Clinical and Pathomorphological Tumor Characteristics.

Authors:  Ieva Golubickaite; Rasa Ugenskiene; Egle Ziliene; Jurgita Beniusyte; Arturas Inciura; Lina Poskiene; Elona Juozaityte
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

3.  Mitochondrial DNA Polymerase POLG1 Disease Mutations and Germline Variants Promote Tumorigenic Properties.

Authors:  Bhupendra Singh; Kjerstin M Owens; Prachi Bajpai; Mohamed Mokhtar Desouki; Vinodh Srinivasasainagendra; Hemant K Tiwari; Keshav K Singh
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

4.  Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity.

Authors:  Kaytee L Pokrzywinski; Thomas G Biel; Dmitry Kryndushkin; V Ashutosh Rao
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

5.  p53 increase mitochondrial copy number via up-regulation of mitochondrial transcription factor A in colorectal cancer.

Authors:  Shilei Wen; Jinhang Gao; Linhao Zhang; Hongying Zhou; Dingzhi Fang; Shi Feng
Journal:  Oncotarget       Date:  2016-11-15

Review 6.  The Landscape of mtDNA Modifications in Cancer: A Tale of Two Cities.

Authors:  Kate L Hertweck; Santanu Dasgupta
Journal:  Front Oncol       Date:  2017-11-02       Impact factor: 6.244

Review 7.  Nuclear genes involved in mitochondrial diseases caused by instability of mitochondrial DNA.

Authors:  Joanna Rusecka; Magdalena Kaliszewska; Ewa Bartnik; Katarzyna Tońska
Journal:  J Appl Genet       Date:  2018-01-17       Impact factor: 3.240

Review 8.  Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease.

Authors:  Raquel Buj; Katherine M Aird
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.